

Test Update: Serum Indices Testing

Pranil K. Chandra, DO, Chief Medical Officer and Vice President, Genomic and Clinical Pathology Services **Adam Meyer, MD,** Associate Medical Director, Clinical Pathology Services

June 25, 2019

Effective **June 10, 2019**, PathGroup has introduced a new automated and semi-quantitative optical measurement system from Roche Diagnostics for the assessment of elevated triglycerides (lipemia), hemoglobin (hemolysis) and bilirubin (icterus) in human serum and plasma specimens. The new procedure will replace the historical subjective visual inspection procedure for marked elevations in these interfering substances. This new procedure will be performed on all plasma and serum specimens with conventional clinical chemistry and immunochemistry tests performed on the Roche analyzers. Please note that serum indices testing is independent from the assessment of unspun or partially spun specimens.

Applicable comments will be added to patient test results with positive findings referencing the specific assay and interfering substance(s). Results will provide clinicians with additional clinical information in conjunction with clinical presentation and history to assist in the diagnosis, treatment, and management of patients.

Sample messages:

Specimen is icteric. Results for Cholesterol, DHEA-Sulfate, GGT, Homocysteine, Total Protein, Ammonia, Creatinine and Triglycerides may be affected. Results should be interpreted in conjunction with clinical presentation and history.

Specimen is lipemic. Results for ALT, AST, Ceruloplasmin, Direct Bilirubin, Haptoglobin, Prealbumin, Progesterone and Ammonia may be affected. Results should be interpreted in conjunction with clinical presentation and history.

Specimen is hemolyzed. Results for Potassium, AST, ALT, Alkaline Phosphatase, CPK, Ammonia, ETOH, GGT, Iron, GlycoMark, Direct Bilirubin, Ferritin, Folate, Haptoglobin, Homocysteine, IgE, Insulin, LDH, PTH and IBC may be affected. Results should be interpreted in conjunction with clinical presentation and history.

For further questions, please contact Client Services at 615-562-9300 or 1-888-474-5227.